Dupilumab Eases Chronic Hand Eczema With or Without Atopic Background

Sixteen weeks of dupilumab improved clinical severity by 59.8% in adults with chronic hand eczema (CHE), compared with 15.2% on placebo, and it did so whether or not those adults carried a history of atopic dermatitis, according to a phase 2b trial conducted in France.¹ The results are meaningful for a population whose hands crack, split, and burn for the better part of a decade with few options once potent topical corticosteroids stop working.

Few Systemic Options Once Topical Steroids Fail

Management of hand eczema has its own European Society of Contact Dermatitis guideline, updated in 2022 to give clinicians current guidance on diagnosis, prevention, and treatment.² The disease it addresses is defined as eczema of the hands persisting beyond 3 months or recurring at least twice within a year, tends to settle in rather than remit, and leaves alitretinoin as the only systemic therapy approved in Europe and Canada for disease refractory to topical treatment.

Etiology in CHE is layered rather than singular, with irritant exposure, contact allergy, and atopic dermatitis frequently overlapping in 1 patient, and that layering has kept the evidence base narrow. Earlier trials of dupilumab, which blocks the interleukin 4 receptor α (IL-4Rα) subunit shared by type 2 cytokine signaling, enrolled only patients whose atopic dermatitis affected the hands or only those with vesicular or chronic fissured subtypes. The broader CHE population, including the substantial share of patients who fit no single category, went untested.

Enrollment Without Etiologic Preselection

The multicenter, double-blind, placebo-controlled trial (NCT03861455) randomly assigned 95 adults across 4 French centers to dupilumab or placebo for 16 weeks, with 94 analyzed after 1 placebo patient was excluded following a COVID-19-related disruption.¹ Randomization was stratified by personal history of atopic dermatitis, but no one was screened in or out on the basis of etiology or clinical morphology.

Participants had a mean age of 39.5 years, 60.6% were women, and CHE had persisted for a mean of 8.72 years. Office workers formed the largest occupational group at 39.4%, followed by health care professionals at 11.7%. A history of atopic dermatitis was present in 68.1% and patient-reported irritant exposure in 46.8%. Allergic contact dermatitis confirmed by relevant positive patch testing was identified in 27.7% of the full cohort, though only 44 of the 94 were actually tested, so the true rate of contact allergy is likely higher. Quality of life at baseline was substantially impaired, with a mean Dermatology Life Quality Index of 12.5 out of 30.

Severity Scores Fell 59.8% With Dupilumab

At week 16, the mean improvement in the modified Total Lesion Symptom Score reached 59.8% (95% CI, 53.1%-66.5%) with dupilumab against 15.2% (95% CI, 4.2%-26.2%) with placebo (P < .001). Eczema elsewhere on the body responded as well, with Eczema Area and Severity Index scores falling 4.2 points (95% CI, 3.6-4.9) vs 0.4 points (95% CI, -1.4 to 2.2) on placebo (P < .001).

Atopic background did not change the answer. Patients whose baseline total immunoglobulin E exceeded 150 kUI/L, reflecting an active atopic profile, improved a mean 57.1% (95% CI, 46.2%-68.0%), against 60.1% (95% CI, 50.0%-70.2%) in those below that threshold. Skin transcriptomics offered a possible explanation: CHE skin shared between 34.1% and 52% of its differentially expressed genes with atopic dermatitis and between 36.4% and 39% with plaque psoriasis, carrying markers of type 1, type 2, and type 3 immunity simultaneously.

“Obviously, CHE should not be classified as a strictly ‘type 2’ disease; however, it may be characterized as a heterogeneous immune condition with a certain degree of IL-4Rα dependence, at least in our cohort of patients,” the authors wrote.

Safety Signals and Study Limits

At least 1 adverse event was reported by 70.2% of the dupilumab group and 83.0% of the placebo group. Mild to moderate ocular events occurred more often with dupilumab, at 23.4% vs 8.5%, though none were severe and none prompted treatment interruption. Two serious events were recorded: an eyelid herpes infection on dupilumab and an eczema flare requiring hospital admission on placebo.

The investigators flagged an atopy-heavy cohort, noting that a mean disease duration approaching 9 years selects for patients likelier to carry an atopic profile and that atopic history and comorbidities were self-reported. Patch testing was not required for enrollment, so contact allergy may be undercounted. The molecular substudies rested on small samples, 15 patients for transcriptomics and 6 for proteomics, and follow-up stopped at week 16.

Sorting these patients into etiologic buckets before deciding whether an IL-4Rα blocker is worth trying may be less informative than it looks, which matters to dermatologists choosing a next step and to payers reviewing the request. What the trial does not supply is durability evidence past 4 months, the kind a formulary decision would want before a biologic displaces topical therapy.

References

1. Gery P, Ekren R, Bérard E, et al. Integrated clinical trial and molecular profiling reveals immune drivers of chronic hand eczema. Allergy. 2026;81(8):2815-2832. doi:10.1111/all.70263

2. Thyssen JP, Schuttelaar MLA, Alfonso JH, et al. Guidelines for diagnosis, prevention, and treatment of hand eczema. Contact Dermatitis. 2022;86(5):357-378. doi:10.1111/cod.14035